target the A subunit of the enzyme and probably interfere with the DNA rejoining step of the gyrase-mediated DNAstrand-passing reaction4~7). Two other types of antibiotics, clerocidin8), and cinodine9), have recently been shown to inhibit bacterial DNAgyrase. Clerocidin was shown to interfere with gyrase-mediated DNA cleavage8). An Escherichia coli mutation conferring resistance to clerocidin was found to map in the gyrA gene8). Cinodine, a glycocinnamoylspermidine antibiotic ( Fig. 1) , is known to bind to DNAand to interfere with DNAsynthesis10). However, at lower concentrations, it was found to inhibit specifically the supercoiling reaction of DNAgyrase in vitro9). In this communication the properties of a cinodine-resistant mutant strain of Escherichia coli are described. The data presented strongly suggest that at low drug concentrations, DNA gyrase is the in vivo target of cinodine. isolated four spontaneous cinodine-resistant mutants. These were picked from a zone of inhibition resulting from a 1jug spot ofcinodine (mixture of the y1 and y2 forms) on a lawn of E. coli strain KNK453,grown at 28°C on an LB1X)plate. The mutant colonies were near the outer edge of the zone. Strain KNK453 is a temperature-sensitive nal derivative of E. coli C12). The mutant colonies appeared after 4 to 5 days of incubation. One mutant, strain MSO101,was characterized, and exhibited low-level resistance to cinodine in vivo.
Strain MSO101grew with a doubling time of 70 minutes at 28°C in the absence of cinodine, in contrast to 60 minutes for the parent strain. Table 1 shows the sensitivity of strain MSO101to cinodine and susceptibility to several other antibacterial agents. In this regard, MSO101differed from the parent and wild type strains only in sensitivity to cinodine and to nalidixic acid (a known inhibitor of DNAgyrase subunit A). MSO101 was four-fold more resistant to cinodine than strain KNK453,and more sensitive to nalidixic acid, suggesting that the new mutation in MSO101resulted in an alteration in DNAgyrase.
DNAGyrase from MSO101was More Resistant to Cinodine Extracts of DNAgyrase from strains MSO101and the parent KNK453 were assayed in vitro for the ability to convert relaxed plasmid pBR322 DNAto the supercoiled form in the presence and absence of cinodine.
Cell extracts were prepared from 500ml of cells grown to late log phase in LB mediumat 28°C. Cells were Cells were grown at 28°C in LBmediumcontaining various concentrations of the indicated antibiotics. The supercoiling reaction of DNAgyrase was carried out at 30°C by the method described previously, using 0. determined by the method of Lowry13). Supercoiling activity of gyrase was measured. by the standard electrophoretic assay method14). The assay used to measure inhibition of supercoiling by novobiocin and cinodine, and quantitation by means of densitometry, were described in detail previously9). The identical assay was used here, except that cell extract was used in place of purified Micrococcus luteus DNAgyrase. Results (Table  2) show that for equal amounts of protein, the gyrase activity of MSO101was four-fold more resistant to cinodine than the gyrase activity of strain KNK453.This result is likely due to either an increased level of gyrase in the mutant strain, or to a genetic alteration in the gyrase structural gene.
Discussion
Results show that a cinodine-resistant mutant of E. coli was approximately 4-fold more resistant to the drug in vivo than the parent strain, and that the mutation resulted in an alteration in DNAgyrase supercoiling activity. The apparent occurrence of cinodine-resistant mutants is quite rare. It was shown previously9) that the inhibitory effect of cinodine on supercoiling occurred at a muchlower concentration than that required to bind to DNAand alter its mobility. The two distinct activities of cinodine are likely to contribute to the difficulty in isolating cinodine-resistant mutants. Thus far cinodine-resistant mutants have been isolated only from E. coli encoding a preexisting mutation in gyrA. This suggests the possibility that the gyrA or other unknown mutation (perhaps acquired by strain KNK453 during passage) may be a prerequisite for identification of a cinodine-resistant mutant. Although cinodine inhibits DNAgyrase at a lower drug concentration than that required to inhibit DNA synthesis, the lethal event in cinodine inhibition of growth is not known. Recently, it was shown that DNA gyrase-quinolone complexes to DNA and blocks transcription in E. coli17). The authors postulated that this blockage may contribute to the lethality of quinolones, since much lower levels of quinolone are needed to inhibit growth than to inhibit supercoiling. Such secondary phenomena may also occur with cinodine, as much lower concentrations of the drug are required to inhibit growth than to inhibit supercoiling in vitro, or DNAsynthesis in vivo10).
